Aclidinium bromide

Not to be confused with Acridinium bromide or Clidinium bromide.
Aclidinium bromide
Systematic (IUPAC) name
[(8R)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-8-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate bromide
Clinical data
Trade names Bretaris Genuair, Eklira Genuair, Tudorza Pressair
Licence data US FDA:link
  • US: C (Risk not ruled out)
Inhalational
Identifiers
320345-99-1 
R03BB05
PubChem CID 11519741
ChemSpider 9694529 
UNII UQW7UF9N91 
KEGG D08837 Yes
ChEBI CHEBI:65344 
ChEMBL CHEMBL551466 
Chemical data
Formula C26H30BrNO4S2
564.555 g/mol
  (what is this?)  (verify)

Aclidinium bromide (INN) is a long-acting, inhaled muscarinic antagonist approved in the US on July 24, 2012[1] as a maintenance treatment for chronic obstructive pulmonary disease (COPD).[2]

Evidence shows that it can improve quality of life and prevent hospitalization in those with COPD.[3] However, it does not appear to affect the risk of death or the frequency steroids are needed.[3] It is unclear if it differs from the similar medication tiotropium or another commonly used medication class of LAMAs.[3]

Aclidinium is delivered via a multidose dry powder inhaler, the Genuair inhaler.

Brand names

It is marketed under the brand name Tudorza Pressair in the US, Eklira Genuair in the UK, and Tudorza Genuair in Canada; licensed to Menarini under the brand name Bretaris Genuair for majority of EU member states[4]

References

  1. ↑ "Forest Laboratories and Almirall Announce FDA Approval of Tudorza™ Pressair™ for the Long-Term Maintenance Treatment of COPD" (Press release). Forest Laboratories. Retrieved 2012-07-24.
  2. ↑ Gavaldà A, Miralpeix M, Ramos I et al. (2009). "Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile". J Pharmacol Exp Ther. Epub ahead of print.
  3. ↑ 3.0 3.1 3.2 Ni, H; Soe, Z; Moe, S (Sep 19, 2014). "Aclidinium bromide for stable chronic obstructive pulmonary disease.". The Cochrane database of systematic reviews 9: CD010509. doi:10.1002/14651858.CD010509.pub2. PMID 25234126.
  4. ↑ "Almirall and Menarini sign a licence agreement and commercial alliance for Aclidinium in the majority of European member states and a number of non-EU countries" (Press release). Menarini. Retrieved 2012-03-26.